| Malignant neoplasm of breast
Talzenna vs Ibrance
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Talzenna vs Ibrance with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsIbrance has a higher rate of injection site reactions vs Talzenna based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ibrance but not Talzenna, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Talzenna
Ibrance
At A Glance
Oral
Daily
PARP inhibitor
Oral
Once daily (21 of 28 days)
CDK4/6 inhibitor
Indications
- Malignant neoplasm of breast
- Hormone refractory prostate cancer
- Malignant neoplasm of breast
Dosing
Malignant neoplasm of breast 1 mg orally once daily until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer 0.5 mg orally once daily with enzalutamide until disease progression or unacceptable toxicity; patients should also receive a GnRH analog concurrently or have had bilateral orchiectomy.
Malignant neoplasm of breast 125 mg orally once daily for 21 consecutive days followed by 7 days off to comprise a 28-day cycle; taken with food. Dose may be reduced to 100 mg or 75 mg for adverse reactions; patients with severe hepatic impairment (Child-Pugh C) start at 75 mg once daily.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Fatigue, nausea, vomiting, diarrhea, headache, alopecia, decreased appetite, hemoglobin decreased, neutrophils decreased, lymphocytes decreased, platelets decreased
Serious Anemia, pyrexia
Most common (>=10%) Neutropenia, infections, leukopenia, fatigue, nausea, alopecia, stomatitis, diarrhea, anemia, rash, asthenia, thrombocytopenia, vomiting, decreased appetite, dry skin, pyrexia, dysgeusia
Serious Neutropenia, leukopenia, infections, anemia
Postmarketing Interstitial lung disease (ILD)/non-infectious pneumonitis, palmar-plantar erythrodysesthesia syndrome (PPES)
Pharmacology
Talazoparib is an inhibitor of PARP enzymes (PARP1 and PARP2) involved in DNA repair; it induces cytotoxicity in cancer cells with DNA repair gene defects through inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage, decreased cell proliferation, and apoptosis.
Palbociclib is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6; it blocks progression of ER-positive breast cancer cells from G1 into S phase of the cell cycle, and in combination with antiestrogens decreases Rb protein phosphorylation, reduces E2F expression, and increases growth arrest.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Talzenna
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Ibrance
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Talzenna
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Ibrance
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (2/8)
Humana
Talzenna
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Ibrance
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Talzenna.
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TalzennaView full Talzenna profile
IbranceView full Ibrance profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.